<DOC>
	<DOC>NCT03062059</DOC>
	<brief_summary>The aim of this study is to evaluate the effectiveness and safety of intravesical gemcitabine instillation during operation to prevent intravesical recurrence after radical nephroureterectomy in upper urinary tract urothelial carcinoma.</brief_summary>
	<brief_title>The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence</brief_title>
	<detailed_description>Study Design: Intervention Model: Single Group Assignment Masking: Open Label Primary Outcome Measures: Two year recurrence-free survival in intravesical 2000mg/52.6ml gemcitabine instillation group and control group. Secondary Outcome Measures: Time to recurrence in intravesical 2000mg/52.6ml gemcitabine instillation group and control group. Overall survival in intravesical 2000mg/52.6ml gemcitabine instillation group and control group. Safety of intravesical 2000mg/52.6ml gemcitabine instillation.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Carcinoma, Transitional Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>The subjects who will undergo nephroureterectomy due to ureter or renal pelvis urothelial carcinoma Male or female aged 18 or over 18 years and not more than 85 years who were diagnosed as upper urinary tract urothelial carcinoma Normal bone marrow function: Hemoglobin &gt;10 g/dL, ANC &gt;1,500/mm3, platelet count&gt;100,000/mm3 Normal bladder volume and function Normal liver function: Bilirubin ≤ 1.5 times of upper normal limit AST/ALT ≤ 1.8 times of upper normal limit Alkaline phosphatase ≤ 1.8 times of upper normal limit Subjects who voluntarily decided to participate and signed the written informed consent Concomitant bladder cancer Subjects who underwent any treatment due to bladder cancer within 3 years Prior hypersensitivity reaction history to gemcitabine Neurogenic bladder Subjects who underwent chemotherapy due to any cancer within 6 months Subjects who underwent neoadjuvant chemotherapy due to ureter or renal pelvis urothelial carcinoma Hypersensitivity to gemcitabine or component of gemcitabine In case of coadministration of gemcitabine and cisplatin in severe renal failure patients Moderate to severe liver dysfunction or renal dysfunction (Glomerular filtration rate &lt; 30 mL/min) Severe bone marrow suppression Severe infection Female who are pregnant or has a possibility of pregnancy Nursing female Interstitial pneumonia or pulmonary fibrosis which is evident on chest xray and symptomatic Subjects who are undergoing radiotherapy on chest</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>